SynthesisOncotarget2016

Is there a benefit of first- or second-line crizotinib in locally advanced or metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer? a meta-analysis.

Hao Hu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.